1. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Issue 6 (15th July 2014) Authors: Mazor, Y.; Almog, R.; Kopylov, U.; Ben Hur, D.; Blatt, A.; Dahan, A.; Waterman, M.; Ben‐Horin, S.; Chowers, Y. Journal: Alimentary pharmacology & therapeutics Issue: Volume 40:Issue 6(2014) Page Start: 620 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Issue 2 (16th November 2016) Authors: Ungar, B.; Kopylov, U.; Engel, T.; Yavzori, M.; Fudim, E.; Picard, O.; Lang, A.; Williet, N.; Paul, S.; Chowers, Y.; Bar‐Gil Shitrit, A.; Eliakim, R.; Ben‐Horin, S.; Roblin, X. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 2(2017) Page Start: 276 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Antigenic response to CT‐P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. Issue 5 (5th June 2018) Authors: Goncalves, J.; Santos, M.; Acurcio, R.; Iria, I.; Gouveia, L.; Matos Brito, P.; Catarina Cunha‐Santos, A.; Barbas, A.; Galvão, J.; Barbosa, I.; Aires da Silva, F.; Alcobia, A.; Cavaco, M.; Cardoso, M.; Delgado Alves, J.; Carey, J. J.; Dörner, T.; Eurico Fonseca, J.; Palmela, C.; Torres, J. Journal: Alimentary pharmacology & therapeutics Issue: Volume 48:Issue 5(2018) Page Start: 507 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Early drug and anti‐infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Issue 2 (9th November 2017) Authors: Bar‐Yoseph, H.; Levhar, N.; Selinger, L.; Manor, U.; Yavzori, M.; Picard, O.; Fudim, E.; Kopylov, U.; Eliakim, R.; Ben‐Horin, S.; Chowers, Y.; Ungar, B. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 2(2018) Page Start: 212 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Editorial: antigenic response to CT‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors' reply. Issue 5 (9th August 2018) Authors: Goncalves, J.; Magro, F.; Danese, S.; Lakatos, P. L.; Ben‐Horin, S. Journal: Alimentary pharmacology & therapeutics Issue: Volume 48:Issue 5(2018) Page Start: 575 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Editorial: restoring therapeutic infliximab drug levels in patients with loss of response—pharmacokinetics and anti‐drug antibodies as useful guidance tools. Issue 6 (15th February 2018) Authors: Ben‐Horin, S. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 6(2018) Page Start: 845 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Issue 12 (19th April 2016) Authors: Ungar, B.; Mazor, Y.; Weisshof, R.; Yanai, H.; Ron, Y.; Goren, I.; Waizbard, A.; Yavzori, M.; Fudim, E.; Picard, O.; Loebstein, R.; Kopylov, U.; Dotan, I.; Chowers, Y.; Eliakim, R.; Ben‐Horin, S. Journal: Alimentary pharmacology & therapeutics Issue: Volume 43:Issue 12(2016) Page Start: 1293 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply. Issue 5 (2nd February 2017) Authors: Ben‐Horin, S.; Ungar, B.; Roblin, X. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 5(2017) Page Start: 760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply. Issue 5 (March 2017) Authors: Ben‐Horin, S.; Ungar, B.; Roblin, X. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 5(2017) Page Start: 760 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor. Issue 8 (15th February 2018) Authors: Ben‐Horin, S.; Ungar, B.; Kopylov, U.; Lahat, A.; Yavzori, M.; Fudim, E.; Picard, O.; Peled, Y.; Eliakim, R.; Del Tedesco, E.; Paul, S.; Roblin, X. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 8(2018) Page Start: 1117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗